Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BAT8001 |
Synonyms | |
Therapy Description |
BAT8001 is an antibody-drug conjugate (ADC) comprising the Erbb2 (Her2)-targeting monoclonal antibody, Trastuzumab, linked to a maytansine-derivative, which delivers the cytotoxic agent to Erbb2-expressing tumor cells, potentially resulting in increased apoptosis and reduced proliferation of tumor cells expressing Erbb2, and decreased tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr CT053; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAT8001 | BAT-8001|BAT 8001|anti-HER2 ADC BAT8001 | HER2 (ERBB2) Antibody 72 HER2 (ERBB2) Antibody-Drug Conjugate 27 | BAT8001 is an antibody-drug conjugate (ADC) comprising the Erbb2 (Her2)-targeting monoclonal antibody, Trastuzumab, linked to a maytansine-derivative, which delivers the cytotoxic agent to Erbb2-expressing tumor cells, potentially resulting in increased apoptosis and reduced proliferation of tumor cells expressing Erbb2, and decreased tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr CT053; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|